REG - Abingdon Health PLC - Director/PDMR Shareholding

Abingdon HealthAnnouncement

25/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231025:nRSY1734Ra&default-theme=true

RNS Number : 1734R  Abingdon Health PLC  25 October 2023

Abingdon Health plc

("Abingdon Health" or the "Company")

 

Director Dealing

 

York, U.K. 25 October 2023: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality, rapid diagnostic
tests announces that on the 24(th) October 2023, Dr Chris Hand, Non-Executive
Chairman purchased ordinary shares of 0.025 pence each in the Company
("Ordinary Shares").

 

Further details are as follows:

 

 Director       No. Ordinary Shares Purchased  Aggregate Purchase Price     Enlarged Holding        Enlarged Holding*

                                               (Pence per Ordinary Share)   (No. Ordinary Shares)   (Per cent. of Total Voting Rights)
 Dr Chris Hand  150,000                        10.167                       13,178,467              10.83%

*Excluding options over Ordinary Shares

 

The Notification of Dealing Form required in accordance with UK MAR is set out
below.

 

Enquiries:

 

 Abingdon Health plc                                              www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                             Via Walbrook PR
 Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)       Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Jalini Kalaravy

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                  (mailto:abingdon@walbrookpr.com)
 Paul McManus, Phillip Marriage,  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 Alice Woodings                   +44 (0)7407 804 654

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Chris Hand

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)               Volume(s)
                                                                                     10 pence per share     100,000

                                                                                     10.5 pence per share   50,000

 d)   Aggregated information

      - Aggregated volume                                          150,000

      - Price                                                      10.167 pence per share

 e)   Date of the transaction                                      24(th) October 2023

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract research ("CRO") and
contract development and manufacturing organisation ("CDMO") offering its
services to an international customer base across industry sectors that
include clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from initial
concept through to routine and large-scale manufacturing; from "idea to
commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test™ range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ™ ecommerce site offers consumers a
range of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKZLFLXBLFFBB